Spark Therapeutics Inc.’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded, paving the way for the first U.S. gene therapy for an inherited disease.
Aerie Pharmaceuticals Inc.’s experimental glaucoma treatment Rhopressa is effective in lowering eye pressure, a preliminary review by the U.S. Food and Drug Administration concluded.
Spark Therapeutics Inc.’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.
Shares of Aerie Pharmaceuticals were soaring more than 35 percent after the company announced Phase III data for its combination glaucoma drug, Roclatan, met efficacy endpoints.
The Bill and Melinda Gates Foundation, Western countries and drug companies pledged fresh support to wipe out diseases in tropical areas.
A thirty-something year old blind woman has her sight restored and sees her young baby for the first time; a 6-year-old boy regains his sight, and for the first time in his life, he sees the face of his parents.
Researchers are warning consumers to be wary of doctors who claim to be able to cure illness using stem cells after three women, at least two who thought they were enrolling in a government-registered trial, were left legally blind when the unproven therapy failed.
Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.
Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, plans to open laboratory and office space in Cambridge, Mass.
Three scientists from Japan, China and Ireland whose discoveries led to the development of potent new drugs against parasitic diseases such as malaria and elephantiasis won the Nobel Prize for […]